The ongoing LIMITS (Levels of Inflammatory Markers in the Treatment of Stroke) study may provide the identification of inflammatory biomarkers, including hs‐CRP, SAA, IL‐6, CD40 ligand (CD40L), TNFR1, and monocyte chemoattractant protein‐1 (MCP‐1), for using in predicting recurrent stroke and other vascular events among patients with a history of small vessel IS or lacunes.96 Here, IL6 is linked to stroke disorder.